Hims & Hers: Testosterone Therapy Boosts Stock

Hims & Hers stock surges as they jump into the $20 million testosterone replacement therapy market! After weight-loss drug sales slowed, the company launched compounded enclomiphene and partnered with Marius Pharmaceuticals for the FDA-approved Kyzatrex (coming in 2026). Is this enough to stabilize the notoriously volatile stock, which has already nearly doubled since January? Find out how this move could impact long-term investors. Hosted on Acast. See acast.com/privacy for more information.